Key facts
- Grove Biopharma’s last known valuation is $64.0M (Apr 2025).
- It has raised $44.0M; the latest was Later Stage VC ($36.0M) in Apr 2025.
- Notable investors include DCVC Bio, Skydeck Capital, Mansueto Office, Deepwork Capital, Eli Lilly — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Grove Biopharma
- ·The full record, as it builds
Funding rounds
No funding rounds for Grove Biopharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Grove Biopharma
Operator of a modality biotechnology company intended to treat unmet medical needs in oncology, chronic inflammatory, and neurodegenerative diseases. The company uses artificial intelligence and precision polymer chemistry to create hybrid synthetic protein mimetics and also offers materials science services to peptide therapeutic challenges, enabling medical professionals with the discovery and development of a new class of synthetic biologic drug modality to access challenging drug targets.
- Sector
- Healthcare
- HQ
- Chicago, IL, United States
- Founded
- 2020
- Employees
- 9
- Website
- grovebiopharma.com/
- Ownership
- Privately Held (backing)
Grove Biopharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Grove Biopharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Grove Biopharma in its N-PORT filings yet. We sweep new filings monthly.